Literature DB >> 19593170

Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

Michael Bauer1, Andrea Pfennig, Michael Linden, Michael N Smolka, Peter Neu, Mazda Adli.   

Abstract

OBJECTIVE: Medication algorithms have been proposed as effective means to offer optimal treatment and improved outcome for patients with severe mental illness. This single-center prospective study compared the efficacy and effects on treatment prescriptions of an algorithm-guided treatment regimen with treatment as usual (TAU) in depressed inpatients.
METHODS: Depressed inpatient participants were randomized to an algorithm-guided standardized stepwise drug treatment regimen (SSTR, n = 74) or TAU (n = 74). The SSTR regimen included sleep deprivation, antidepressant monotherapy, lithium augmentation, monoamine oxidase inhibitor therapy, or electroconvulsive therapy guided by scores on the clinician-rated Bech-Rafaelsen Melancholia Scale. The primary outcome was time to remission (defined as a Bech-Rafaelsen Melancholia Scale score of < or =7). Secondary outcomes were remission rates, number of changes in treatment strategies (types), and the number of different prescribed medications over the treatment period.
RESULTS: Patients receiving SSTR had a significantly shorter time to remission (7.0 +/- 0.9 weeks vs 12.3 +/- 1.8 weeks for TAU). Compared with that in remitters in SSTR, the number of strategy changes was significantly higher in TAU remitters (3.0 +/- 2.7 and 1.0 +/- 1.5) and had more psychotropic medications (fix agents: 3.0 +/- 1.5 and 1.9 +/- 1.1; optional agents: 1.5 +/- 1.0 and 0.9 +/- 0.7). Although more patients dropped out of the SSTR group (33 of SSTR, 12 of TAU), the probability of remission tended to be higher in SSTR.
CONCLUSIONS: Algorithm-guided treatment produces better outcomes and less frequent medication changes than TAU. A systematic, stepwise, measurement-based approach to the treatment of depressed inpatients is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593170     DOI: 10.1097/JCP.0b013e3181ac4839

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  21 in total

Review 1.  [Treatment pathways in the care of patients with schizophrenia and depression].

Authors:  H J Salize; E Voß; A Werner; P Falkai; I Hauth
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  [Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].

Authors:  G Juckel; K Stahl; C Norra
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

Review 3.  [Electroconvulsive therapy for the treatment of major depression].

Authors:  D Zilles; C Wolff-Menzler; J Wiltfang
Journal:  Nervenarzt       Date:  2015-05       Impact factor: 1.214

4.  The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.

Authors:  Søren D Østergaard; Leslie Foldager; Ole Mors; Per Bech; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

Review 5.  Treatment of depression in older adults.

Authors:  Cássio M C Bottino; Ricardo Barcelos-Ferreira; Salma R I Ribeiz
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

6.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

7.  Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan J Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-15       Impact factor: 5.270

8.  Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

Authors:  Lobna Ibrahim; Nancy Diazgranados; David A Luckenbaugh; Rodrigo Machado-Vieira; Jacqueline Baumann; Alan G Mallinger; Carlos A Zarate
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-04-03       Impact factor: 5.067

Review 9.  Chronic and treatment resistant depression: diagnosis and stepwise therapy.

Authors:  Tom Bschor; Michael Bauer; Mazda Adli
Journal:  Dtsch Arztebl Int       Date:  2014-11-07       Impact factor: 5.594

10.  Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes.

Authors:  Johannes Rentzsch; Mazda Adli; Katja Wiethoff; Ana Gómez-Carrillo de Castro; Jürgen Gallinat
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-20       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.